UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

NOTICE OF EFFECTIVENESS

Effective Date:January 17,
Boundless Bio (NASDAQ:BOLD)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Boundless Bio Charts.
Boundless Bio (NASDAQ:BOLD)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Boundless Bio Charts.

Audentes Therapeutics, Inc. News

Form 4 - Statement of changes in beneficial ownership of securities
Monday 3 February 2025 (2 weeks ago) • Edgar (US Regulatory)
Form 3 - Initial statement of beneficial ownership of securities
Monday 3 February 2025 (2 weeks ago) • Edgar (US Regulatory)
Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer
Monday 3 February 2025 (2 weeks ago) • GlobeNewswire Inc.
Form 8-K - Current report
Thursday 12 December 2024 (2 months ago) • Edgar (US Regulatory)
Boundless Bio Announces Pipeline and Leadership Updates
Thursday 12 December 2024 (2 months ago) • GlobeNewswire Inc.
Boundless Bio to Participate in the Piper Sandler Healthcare Conference
Monday 25 November 2024 (3 months ago) • GlobeNewswire Inc.
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 7 November 2024 (3 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Thursday 7 November 2024 (3 months ago) • Edgar (US Regulatory)
Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights
Thursday 7 November 2024 (3 months ago) • GlobeNewswire Inc.
Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference
Tuesday 5 November 2024 (3 months ago) • GlobeNewswire Inc.
Form 8-K - Current report
Tuesday 15 October 2024 (4 months ago) • Edgar (US Regulatory)
Boundless Bio Announces Departure of Chief Financial Officer
Monday 14 October 2024 (4 months ago) • GlobeNewswire Inc.

More Audentes Therapeutics, Inc. News Articles

Your Recent History

LSE
0G4L
Beowulf Mining
FX
AEDSAR
AED vs SAR
Delayed Upgrade Clock

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads